Sexually transmitted diseases and infections

Oncorus Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

Retrieved on: 
Wednesday, January 20, 2021
Medical specialties, Clinical medicine, Medicine, Virotherapy, Sexually transmitted diseases and infections, Oncolytic virus, Herpes simplex, Immunotherapy, Programmed cell death protein 1, Talimogene laherparepvec, Gabriella Campadelli-Fiume

, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, announced today the recent publication of preclinical data supporting the clinical development of its lead oncolytic Herpes Simplex Virus (oHSV) clinical candidate, ONCR-177.

Key Points: 
  • , Jan. 20, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, announced today the recent publication of preclinical data supporting the clinical development of its lead oncolytic Herpes Simplex Virus (oHSV) clinical candidate, ONCR-177.
  • A herpes simplex virus 1 (HSV-1) gene, 34.5 allows the virus to replicate in the presence of host antiviral immune responses.
  • We are pleased to share these encouraging preclinical findings, which supported our advancement of ONCR-177 into clinical development last year.
  • The addition of systemic anti-PD-1 augmented the activity of mONCR-171, particularly for un-injected tumors, suggesting that utilizing systemic anti-PD-1 immunotherapy may augment the systemic antitumor effect of ONCR-177.

Herpesyl Review: Get Rid of Herpes Virus with This Supplement

Retrieved on: 
Tuesday, January 12, 2021
Medical specialties, Sexually transmitted diseases and infections, Virology, Herpes, Clinical medicine, Viral diseases, Biology of bipolar disorder, Herpes simplex, Genital herpes, Herpetic gingivostomatitis, Infection, Herpes simplex research

NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Herpesyl is a natural supplement that helps people to fight herpes symptoms.

Key Points: 
  • NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Herpesyl is a natural supplement that helps people to fight herpes symptoms.
  • There are two types of Herpes infection, genital Herpes, and Oral Herpes.
  • According to the manufacturer of Herpesyl , it is a perfect blend of natural ingredients, which makes it a potent supplement like drugs used to treat Herpes.
  • Herpesyl is an effective supplement that works best for herpes outbreaks to treat the inner cause of herpes infection.

Herpesyl Review: Get Rid of Herpes Virus with This Supplement

Retrieved on: 
Tuesday, January 12, 2021
Medical specialties, Sexually transmitted diseases and infections, Virology, Herpes, Clinical medicine, Viral diseases, Biology of bipolar disorder, Herpes simplex, Genital herpes, Herpetic gingivostomatitis, Infection, Herpes simplex research

NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Herpesyl is a natural supplement that helps people to fight herpes symptoms.

Key Points: 
  • NEW YORK, Jan. 12, 2021 /PRNewswire/ -- Herpesyl is a natural supplement that helps people to fight herpes symptoms.
  • There are two types of Herpes infection, genital Herpes, and Oral Herpes.
  • According to the manufacturer of Herpesyl , it is a perfect blend of natural ingredients, which makes it a potent supplement like drugs used to treat Herpes.
  • Herpesyl is an effective supplement that works best for herpes outbreaks to treat the inner cause of herpes infection.

Journal of Virology publishes paper on Rational Vaccines live-attenuated vaccine candidate

Retrieved on: 
Monday, January 11, 2021
Medical specialties, Sexually transmitted diseases and infections, Microbiology, Branches of biology, Vaccination, Virology, Herpes simplex virus, Herpes simplex, Herpes simplex research, Vaccine, HSV-2, HSV

CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- A study of Rational Vaccines' herpes simplex virus candidate published in the Journal of Virology demonstrates that the vaccine candidate, RVX10,offered robust protection against ocular herpes simplex virus 1 (HSV-1) infection in vaccinated mice.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- A study of Rational Vaccines' herpes simplex virus candidate published in the Journal of Virology demonstrates that the vaccine candidate, RVX10,offered robust protection against ocular herpes simplex virus 1 (HSV-1) infection in vaccinated mice.
  • This robust efficacy was found to be correlated with CD8+ T cells, since depleting these cells after vaccination, but before challenge with HSV-1 eliminated any efficacy realized by the vaccine.
  • Ocular HSV can cause disease in any layer of the eye and is mainly spread by direct contact.
  • Rational Vaccines develops rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates, particularly focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.

H2 2020 Pipeline Review on Herpes Labialis (Oral Herpes) - Product Development Milestones - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 7, 2021
Health, Pharmaceutical, Medical specialties, Viral diseases, Clinical medicine, Virology, Sexually transmitted diseases and infections, Biology of bipolar disorder, Herpes simplex, Herpetic gingivostomatitis, Herpes labialis, Infectious disease, Infection

The "Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Herpes Labialis (Oral Herpes) - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • It also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects.
  • The pipeline guide reviews key companies involved in Herpes Labialis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

HSV Eraser Review: PDF eBook For Permanently Eliminate the Herpes Virus from One's Body

Retrieved on: 
Tuesday, December 29, 2020
Sexually transmitted diseases and infections, Medical specialties, Virology, Viral diseases, Herpes, Infectious diseases, Biology of bipolar disorder, Herpes simplex, HSV-2, HSV, Herpes simplex research

Readers should know that there are two types of the herpes virus, HSV1, and HSV2.

Key Points: 
  • Readers should know that there are two types of the herpes virus, HSV1, and HSV2.
  • Now, the HSV Eraser Review is a 21-day program kit that helps in the treatment of herpes .
  • The more conventional treatment doesn't permanently wipe away the virus from the body.
  • On the other hand, HSV Eraser Reviewis a cure that will help users to get rid of the virus permanently.

HSV Eraser Review: PDF eBook For Permanently Eliminate the Herpes Virus from One's Body

Retrieved on: 
Tuesday, December 29, 2020
Sexually transmitted diseases and infections, Medical specialties, Virology, Viral diseases, Herpes, Infectious diseases, Biology of bipolar disorder, Herpes simplex, HSV-2, HSV, Herpes simplex research

Readers should know that there are two types of the herpes virus, HSV1, and HSV2.

Key Points: 
  • Readers should know that there are two types of the herpes virus, HSV1, and HSV2.
  • Now, the HSV Eraser Review is a 21-day program kit that helps in the treatment of herpes .
  • The more conventional treatment doesn't permanently wipe away the virus from the body.
  • On the other hand, HSV Eraser Reviewis a cure that will help users to get rid of the virus permanently.

HIV is turning gray: Will the Biden White House Accept the Challenge?

Retrieved on: 
Friday, December 18, 2020
Medical specialties, Retroviridae, Hepatotoxins, Sexually transmitted diseases and infections, Articles, Management of HIV/AIDS, HIV/AIDS, HIV, Treatment as prevention, AIDS service organization

Some years later, the human immunodeficiency virus (HIV) caused AIDS was discovered, and it started the dark legacy that lives on today.

Key Points: 
  • Some years later, the human immunodeficiency virus (HIV) caused AIDS was discovered, and it started the dark legacy that lives on today.
  • Significant advances in care and treatment mean people with HIV are living longer.
  • In the U.S. today, young adults with HIV-infection who adhere to their antiretroviral treatment maintain lower viral loads and live longer.
  • Older HIV patients struggle to cope with many obstacles among them mental health problems, homelessness, and co-morbidities daily.

Global Chlamydia Infection Diagnostics and Therapeutics Industry (2020 to 2027) - Market Trends and Drivers - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 16, 2020
Health, Infectious diseases, Chlamydiae, Sexually transmitted diseases and infections, Chlamydia

The "Chlamydia Infection Diagnostics and Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chlamydia Infection Diagnostics and Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • The 284-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021.
  • Amid the COVID-19 crisis, the global market for Chlamydia Infection Diagnostics and Therapeutics estimated at US$1.4 Billion in the year 2020, is projected to reach a revised size of US$1.9 Billion by 2027, growing at a CAGR of 4.9% over the period 2020-2027.
  • The U.S. Market is Estimated at $373.7 Million, While China is Forecast to Grow at 7.5% CAGR
    The Chlamydia Infection Diagnostics and Therapeutics market in the U.S. is estimated at US$373.7 Million in the year 2020.

DGAP-News: New Worldwide Patents Issued on Discovery for Botulinum NeuroToxin in Combination with Silver Nano Particles Creating Extraordinary Outcomes

Retrieved on: 
Wednesday, December 16, 2020
Medical specialties, Drugs, Clinical medicine, Sexually transmitted diseases and infections, Botulism, Viral diseases, Neurotoxin, Herpes simplex virus, Botulinum toxin, Nano, Herpes labialis

Willoughby and Dr. Keith W. Moeller have been granted and issued numerous patents worldwide - including in Asia, Europe, and now the United States - on the combination and utilization of Nano-Silver with various Botulinum NeuroToxins ("BONTs").

Key Points: 
  • Willoughby and Dr. Keith W. Moeller have been granted and issued numerous patents worldwide - including in Asia, Europe, and now the United States - on the combination and utilization of Nano-Silver with various Botulinum NeuroToxins ("BONTs").
  • There were also notable anti-viral effects in patients with cold sores (HSV-1), and none of these patients experienced any adverse events.
  • We also have a completed IRB-sponsored Phase-2 human ingestion study - the largest of its kind ever performed with a Nano-Silver compound.
  • 16.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.